Our GLP-1 products have a long history of use in treating Type 2 diabetes (over 19 years) and obesity (almost 10 years), supported by robust clinical data and over 22 million patient years of exposure, the company notes in a statement
We serve clients from Orlando FL, Winter Park FL, Maitland FL, Baldwin Park FL, Altamonte Springs FL, and surrounding areas
Diabetes Care 2018;41:26692701 [DOI] [PMC free article] [PubMed] [Google Scholar] 5.Buse JB, Wexler DJ, Tsapas A, et al
If patients with type two diabetes were to stop taking GLP-1 agonists, their blood sugar would uptick, leading to other diabetes complications
The SUSTAIN clinical trial program, which evaluated semaglutide in patients with type 2 diabetes, showed average systolic blood pressure reductions of 37 mmHg across multiple studies, with smaller decreases in diastolic blood pressure
10.2337/dc23-S008 [DOI] [PMC free article] [PubMed] [Google Scholar] 3.ElSayed NA, Aleppo G, Aroda VR et al (2023) 6